Skip to main content
  • Register
  • Help
  • Contact us

Forte Biosciences Inc (FBRX) NPV

Sell:$33.00 Buy:$33.50 Change: $0.64 (2.00%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:$33.00
Buy:$33.50
Change: $0.64 (2.00%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:$33.00
Buy:$33.50
Change: $0.64 (2.00%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Forte Biosciences, Inc., formerly Tocagen Inc., is a clinical-stage biopharmaceutical company. The Company is focused on clinical program and developing a live biotherapeutic for the treatment of inflammatory skin diseases, particularly for pediatric atopic dermatitis patients. It provides FB-401, which is a live biotherapeutic for the treatment of inflammatory skin diseases. FB-401 has completed Phase I/II a testing in adult and pediatric patients with atopic dermatitis.

Contact details

Address:
1124 W Carson Street, Mrl Building 3-320
TORRANCE
90502
United States
Telephone:
+1 (310) 6186994
Website:
https://www.fortebiorx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
FBRX
ISIN:
US34962G1094
Market cap:
$465.88 million
Shares in issue:
13.51 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Paul Wagner
    Chairman of the Board, President, Chief Executive Officer
  • Antony Riley
    Chief Financial Officer
  • Fairooz Kabbinavar
    Senior Vice President, Clinical Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.